
Bioventus (BVS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Bioventus (BVS) last issued guidance on November 2, 2026 for fiscal year 2026. The company guided earnings per share in the range of $0.75 - $0.79, compared to a consensus EPS estimate of $0.78. Bioventus also guided revenue in the range of $590M - $595M for the period.
Compared to prior guidance, Bioventus maintained its EPS outlook from a previous range of $0.75 - $0.79. On the revenue side, the company lowered its revenue forecast from a prior range of $600M - $610M.
Bioventus has issued 16 guidance updates between November 8, 2022 and November 2, 2026. During this period, the company raised its outlook 7 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.16 | $0.21 | $0.07 | $0.22 |
| Actual | $0.17 | $0.22 | $0.15 | $0.24 |
| Surprise | +6.25% | +4.76% | +114.3% | +9.09% |
| Revenue | ||||
| Estimate | $149.5M | $155.3M | $129.8M | $154.0M |
| Actual | $142.4M | $153.2M | $132.1M | $157.9M |
| Surprise | -4.74% | -1.32% | +1.80% | +2.50% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.17 | $0.15 | $0.25 | $0.20 |
| Revenue | ||||
| Consensus | $146.1M | $140.3M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 2, 2026 | $0.17 | $0.16 | 6.25 % |
| Q2 | Aug 5, 2026 | $0.22 | $0.21 | 4.76 % |
| Q1 | May 6, 2026 | $0.15 | $0.07 | 114.3 % |
| Q4 | Mar 5, 2026 | $0.24 | $0.22 | 9.09 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 2, 2026 | $142.44M | $149.52M | -4.74 % |
| Q2 | Aug 5, 2026 | $153.21M | $155.26M | -1.32 % |
| Q1 | May 6, 2026 | $132.09M | $129.75M | 1.80 % |
| Q4 | Mar 5, 2026 | $157.90M | $154.04M | 2.50 % |